Monitoring infection with Epstein-Barr virus among seromismatch adult renal transplant recipients

American Journal of Transplantation

Volumn 11, Issue 5, 2011, Pages 1058-1063

  Martin, S I ^a   Dodson, B ^b   Wheeler, C ^a   Davis, J ^a   Pesavento, T ^a   Bumgardner, G L ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Epstein Barr virus (EBV); post transplant lymphoproliferative disorder (PTLD); renal transplant; rituximab

Indexed keywords

RITUXIMAB;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; EPSTEIN BARR VIRUS INFECTION; FEMALE; GRAFT FAILURE; GRAFT RECIPIENT; HIGH RISK POPULATION; HUMAN; KIDNEY GRAFT; KIDNEY PANCREAS TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MALE; PRIORITY JOURNAL; SEROCONVERSION; VIREMIA;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK; VIRAL LOAD;

EID: 79955543317     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03478.x     Document Type: Article

References (16)

1. Taylor AL, Marcus R, Bradley JA,. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. Crit Rev Oncol Hematol 2005; 56: 155-167. (Pubitemid 41278654)
2. Opelz G, Dohler B,. Lymphomas after solid organ transplantation: A collaborative transplant study report. Am J Transplant 2004; 4: 222-230. (Pubitemid 38248525)
3. Allen U, Preiksaitis J,. Epstein-Barr virus and posttransplant lymphoproliferative disorder in solid organ transplant recipients. Am J Transplant 2009; 9 (Suppl 4): S87-S96.
4. Humar A, Hebert D, Davies HD, et al,. A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder. Transplantation 2006; 81: 856-861.
5. Paya CV, Fung JJ, Nalesnik MA, et al,. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation 1999; 68: 1517-1525.
6. Roychowdhury S, Peng R, Baiocchi RA, et al,. Experimental treatment of Epstein-Barr virus-associated primary central nervous system lymphoma. Cancer Res 2003; 63: 965-971. (Pubitemid 36278426)
7. Lee TC, Savoldo B, Rooney CM, et al,. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant 2005; 5: 2222-2228. (Pubitemid 41648469)
8. McDiarmid SV, Jordan S, Kim GS, et al,. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients. Transplantation 1998; 66: 1604-1611. (Pubitemid 29034978)
9. Tsai DE, Hardy CL, Tomaszewski JE, et al,. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: Analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 2001; 71: 1076-1088. (Pubitemid 32448822)
10. Stevens SJ, Verschuuren EA, Pronk I, et al,. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood 2001; 97: 1165-1171. (Pubitemid 32183736)
11. Biasolo MA, Calistri A, Cesaro S, Gentile G, Mengoli C, Palu G,. Case report: Kinetics of Epstein-Barr virus load in a bone marrow transplant patient with no sign of lymphoproliferative disease. J Med Virol 2003; 69: 220-224. (Pubitemid 36068878)
12. Svoboda J, Kotloff R, Tsai DE,. Management of patients with post-transplant lymphoproliferative disorder: The role of rituximab. Transpl Int 2006; 19: 259-269.
13. van Esser JW, Niesters HG, Van Der Holt B, et al,. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 2002; 99: 4364-4369. (Pubitemid 34627202)
14. Omar H, Hagglund H, Gustafsson-Jernberg A, et al,. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction. Transpl Infect Dis 2009; 11: 393-399.
15. Grim SA, Pham T, Thielke J, et al,. Infectious complications associated with the use of rituximab for ABO-incompatible and positive cross-match renal transplant recipients. Clin Transplant 2007; 21: 628-632. (Pubitemid 47399427)
16. Kamar N, Milioto O, Puissant-Lubrano B, et al,. Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients. Am J Transplant 10: 89-98.